SYK inhibition targets acute myeloid leukemia stem cells by blocking their oxidative metabolismAnna Polak, Przemysław Juszczyński, Emilia Białopiotrowicz et al.|Cell Death and Disease|2020Cited by 41
Persistent imbalance, anti-apoptotic, and anti-inflammatory signature of circulating C-C chemokines and cytokines in patients with paroxysmal nocturnal hemoglobinuriaUrszula Szlendak, Jacek Nowak, Ewa Mendek‐Czajkowska et al.|Cytokine|2021Cited by 1
A compelling case for central pathology review of multiparameter flow cytometry measurable residual disease results in Acute Myeloid Leukemia (AML) clinical trials: Data from the PALG-AML1/2016 multicenter randomized studyAgnieszka Wierzbowska, Gail J. Roboz, Anna Czyż et al.|Blood|2025Cited by 1
PS986 SYK‐DEPENDENT P‐STAT5 ACTIVITY IS REQUIRED TO MAINTAIN CLONOGENIC POTENTIAL AND OXPHOS METABOLISM IN ACUTE MYELOID LEUKEMIA (AML) CELLSAnna Polak, Przemysław Juszczyński, Emilia Białopiotrowicz et al.|HemaSphere|2019Cited by 0
Prospective Assessment of Measurable Residual Disease Kinetics in Intensively Treated Patients with Acute Myeloid Leukemia - Results of the Polish Adult Leukemia Group PALG-AML1/2016 StudyAgnieszka Wierzbowska, Gail J. Roboz, Agnieszka Pluta et al.|Blood|2022Cited by 0